-
EP1668142
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1668142
| EP1668142 - MODIFIED VACCINIA VIRUS ANKARA (MVA) MUTANT AND USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.08.2014 Database last updated on 11.04.2026 | Most recent event Tooltip | 01.08.2014 | Application deemed to be withdrawn | published on 03.09.2014 [2014/36] | Applicant(s) | For all designated states Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ingolstädter Landstrasse 1 85764 Neuherberg / DE | [2008/12] |
| Former [2006/24] | For all designated states GSF-Forschungszentrum für Umwelt und Gesundheit GmbH 80807 Oberschleissheim / DE | Inventor(s) | 01 /
STAIB, Caroline Degenfeldstr. 9 80803 München / DE | 02 /
SUTTER, Gerd Unertlstrasse 4 80803 Muenchen / DE | 03 /
KIESLING, Sigrid Melchweg 7 85652 Pliening / DE | 04 /
ERFLE, Volker Laplacestrasse 4 81679 Muenchen / DE | [2007/10] |
| Former [2006/24] | 01 /
STAIB, Caroline Speyererstrasse 6 80804 Muenchen / DE | ||
| 02 /
SUTTER, Gerd Unertlstrasse 4 80803 Muenchen / DE | |||
| 03 /
KIESLING, Sigried Boschetsriederstrasse 59 81379 Muenchen / DE | |||
| 04 /
ERFLE, Volker Laplacestrasse 4 81679 Muenchen / DE | Representative(s) | Isarpatent Patent- und Rechtsanwälte Barth Charles Hassa Peckmann & Partner mbB Postfach 44 01 51 80750 München / DE | [N/P] |
| Former [2012/18] | Isarpatent Patent- und Rechtsanwälte Postfach 44 01 51 80750 München / DE | ||
| Former [2008/33] | Behnisch, Werner Reinhard-Skuhra-Weise & Partner GbR Patentanwälte Friedrichstrasse 31 80801 München / DE | ||
| Former [2006/24] | Behnisch, Werner Reinhard-Skuhra-Weise Friedrichstrasse 31 80801 München / DE | Application number, filing date | 04765665.7 | 28.09.2004 | [2006/24] | WO2004EP10858 | Priority number, date | EP20030022112 | 29.09.2003 Original published format: EP 03022112 | [2006/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2005030971 | Date: | 07.04.2005 | Language: | EN | [2005/14] | Type: | A1 Application with search report | No.: | EP1668142 | Date: | 14.06.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.04.2005 takes the place of the publication of the European patent application. | [2006/24] | Search report(s) | International search report - published on: | EP | 07.04.2005 | Classification | IPC: | C12N15/86, A61K39/285, A61P37/00 | [2006/24] | CPC: |
C12N15/86 (EP,US);
A61K39/12 (EP,US);
A61K39/285 (EP,US);
A61P37/00 (EP);
A61K2039/5252 (EP,US);
A61K2039/5256 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/24] | Extension states | AL | Not yet paid | HR | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | MUTANTE DES MODIFIZIERTEN VACCINIAVIRUS ANKARA (MVA) UND VERWENDUNG DAVON | [2006/24] | English: | MODIFIED VACCINIA VIRUS ANKARA (MVA) MUTANT AND USE THEREOF | [2006/24] | French: | MUTANT DU VIRUS DE LA VACCINE ANKARA MODIFIE (MVA) ET UTILISATION CORRESPONDANTE | [2006/24] | Entry into regional phase | 15.03.2006 | National basic fee paid | 15.03.2006 | Designation fee(s) paid | 15.03.2006 | Examination fee paid | Examination procedure | 15.03.2006 | Amendment by applicant (claims and/or description) | 15.03.2006 | Examination requested [2006/24] | 20.03.2009 | Despatch of a communication from the examining division (Time limit: M04) | 27.07.2009 | Reply to a communication from the examining division | 04.07.2011 | Despatch of a communication from the examining division (Time limit: M06) | 30.12.2011 | Reply to a communication from the examining division | 01.04.2014 | Application deemed to be withdrawn, date of legal effect [2014/36] | 29.04.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2014/36] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.03.2009 | Fees paid | Renewal fee | 29.09.2006 | Renewal fee patent year 03 | 28.09.2007 | Renewal fee patent year 04 | 02.10.2008 | Renewal fee patent year 05 | 30.09.2009 | Renewal fee patent year 06 | 30.09.2010 | Renewal fee patent year 07 | 30.09.2011 | Renewal fee patent year 08 | 28.09.2012 | Renewal fee patent year 09 | Penalty fee | Additional fee for renewal fee | 30.09.2008 | 05 M06 Fee paid on 02.10.2008 | 30.09.2013 | 10 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XD] C. STAIB ET AL.: "TRANSIENT HOST RANGE SELECTION FOR GENETIC ENGINEERING OF MODIFIED VACCINIA VIRUS ANKARA", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 28, no. 6, June 2000 (2000-06-01), pages 1137 - 1148, XP001026101, ISSN: 0736-6205 * like Staib et al. * | [A] ALCAMI A. ET AL.: "A soluble receptor for interleukin-1-beta encoded by vaccinia virus: A novel mechanism of virus modulation of the host response to infection", CELL, vol. 71, no. 1, 2 October 1992 (1992-10-02), pages 153 - 167, XP001156874 [A] 1-11 * page 11030, column 1, paragraph 3 - page 11031, column 1, paragraph 2 * * page 11032, column 1, paragraph 1 - page 11033, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1016/0092-8674(92)90274-G | [A] SPRIGGS MELANIE K ET AL: "Vaccinia and cowpox viruses encode a novel secreted interleukin-1 binding protein", CELL, vol. 71, no. 1, 1992, pages 145 - 152, XP001157012, ISSN: 0092-8674 DOI: http://dx.doi.org/10.1016/0092-8674(92)90273-F | [A] KETTLE SUSAN ET AL: "Vaccinia virus serpin B1 3R (SPI-2) inhibits interleukin-1-beta-converting enzyme and protects virus- infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1-beta-induced fever", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 3, 1997, pages 677 - 685, XP002266345, ISSN: 0022-1317 | Examination | DE2145477 | WO0073476 | WO0168820 |